It’s a pill. It’s a device. It’s both. FDA Approves the first Digital Drug Therapy

Adherence to prescription drug therapies is a big problem, not only for patients and drug developers, but also for payers who cover the costs of such medications and then pay to treat problems the drugs were meant to prevent. About… Read »

A New Precision Medicine Initiative in Parkinson’s Disease… and Perhaps Other Neurologic Conditions

Cancer was once considered a single disease, but today we are well aware of the many different forms this medical scourge can take, and the many molecular events that can lead to and drive unwanted cell growth. Now, a new… Read »

Giving Thanks in IO

The immuno-oncology (IO) field has a lot to be thankful for as the year comes to a close.   Not only are PD-1/PDL-1 inhibitors being rapidly approved, their use is being extended into new indications and tumor types well beyond… Read »

Kite Gains First Adult CAR-T Approval

Less than two weeks following the closing of Gilead’s acquisition of the company, Kite Pharma’s CAR-T immunotherapeutic, axicabtagene ciloleucel, has gained approval from the U.S. Food and Drug Administration as the first CAR-T therapy for an adult indication. The approval,… Read »

Gene Therapy for Inherited Retinal Disease Achieves a Historic Milestone

This has been an amazing year in the world of drug development, with three new therapeutic classes marking historic gains. We first saw Novartis’ FDA approval for the first CAR-T immunotherapy. Then Alnylam’s RNAi treatment achieved Phase 3 success, the… Read »

Search for an Alzheimer’s Treatment Goes On

Anticipation was high for the results of a Phase 3 trial of Axovant’s experimental drug, interpirdine. Sadly, the potential Alzheimer’s disease treatment failed to meet its co-primary endpoints. Patients with mild to moderate Alzheimer’s disease who were treated for 24… Read »

RNA Interference Achieves Key Milestone with Patisiran Success

It is a not uncommon phenomenon for a new discovery to attract much enthusiasm and hype — as well as investment and new company formation — only to suffer popular disillusionment a few years later as public interest turns to… Read »

ESMO 2017 — Part 2: Building on Biomarkers

The news from ESMO in September once again has highlighted the utility and need for biomarkers to help determine not only who will likely benefit from a particular immuno-oncology (IO) treatment, but also who may require a combination of such… Read »

ESMO 2017 — Recent Developments in the Oncology Arena — Part One

We recently returned from the European Society for Medical Oncology (ESMO) 2017 meeting, which is the major meeting for oncology professionals in Europe, attracting over 24,000 participants from 131 countries.  This fall meeting saw a lot of news, notably in… Read »

Alzheimer’s Disease and the Diagnostic Dilemma

Head over to LinkedIn to read an article by our principal consultant Rachel Laing as part of our continuing commentary on Alzheimer’s Disease. https://www.linkedin.com/pulse/alzheimers-disease-diagnostic-dilemma-rachel-laing/  

1 2 3 8